Protalix BioTherapeutics Inc (PLX)

0.57
AMEX : Health Care
Prev Close 0.60
Day Low/High 0.56 / 0.61
52 Wk Low/High 0.58 / 1.43
Avg Volume 119.30K
Exchange AMEX
Shares Outstanding 99.81M
Market Cap 59.88M
EPS 0.60
P/E Ratio 2.59
Div & Yield N.A. (N.A)

Latest News

IIROC Trading Resumption - PLX

IIROC Trading Resumption - PLX

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Protalix BioTherapeutics To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF

Positive Pre-Clinical Data for PRX-106 Oral Anti-TNF in NASH

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Net Losses Narrowed With Clinical Progress in All Three Product Candidates

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF

Favorable Safety and Tolerability Data Demonstrates Biological Activity in the Gut and Activation of Regulatory T Cells

Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease

Protalix BioTherapeutics Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease

Interim Efficacy and Safety Results to be Presented at WORLD Symposium